Regorafenib (Belvango) usage and dosage and dosage adjustment for different patients

Regorafenib is an oral multi-target tyrosine kinase inhibitor mainly used to treat patients with advanced tumors such as metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumors. Standard usage is oral administration, once a day, for 21 consecutive days, followed by a 7-day break, constituting a 28-day treatment cycle. Patients should strictly follow the doctor's instructions and should not increase or decrease the dosage or change the medication cycle at will to ensure the efficacy and safety of the drug.

The recommended starting dose for adult patients is usually 160mg (4 tablets, each tablet 40mg), taken with food to reduce the occurrence of gastrointestinal discomfort. When taking the medicine, the tablet should be swallowed whole and should not be chewed or crushed to ensure sustained release and absorption of the medicine. If the patient experiences mild to moderate adverse reactions, appropriate symptomatic treatment, such as anti-nausea drugs, antidiarrheal drugs or supportive therapy, can be taken under the guidance of a doctor.

For weak, elderly patients or those with severe liver damage, the starting dose may need to be adjusted to 120mg or 80mg daily, and blood routine, liver and kidney function, blood pressure and other indicators should be closely monitored during treatment. If the patient tolerates it well, it can be gradually increased to the recommended dose under the guidance of a doctor to obtain the best therapeutic effect. If severe toxic reactions occur, the medication should be suspended and the medication can be continued or the dose can be further adjusted after the symptoms are relieved.

In addition, dosage adjustments may vary among patients with different disease types. For example, patients with hepatocellular carcinoma may need more careful dose management due to liver function affecting drug metabolism; and patients with colorectal cancer who are combined with multiple targeted therapies may need individualized dose adjustments based on drug interactions. Generally speaking, the usage and dosage of regorafenib should be based on the patient's age, physical condition, liver and kidney function, and disease type, and should be managed individually by professional doctors to ensure maximum efficacy and reduce the risk of adverse reactions.

Reference link:https://www.drugs.com